Camsirubicin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Camsirubicin
DrugBank Accession Number
DB13103
Background

GPX-150 has been used in trials studying the treatment of Soft Tissue Sarcoma and Advanced Solid Tumors - Phase 1 Population.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 542.541
Monoisotopic: 542.190045174
Chemical Formula
C27H30N2O10
Synonyms
  • 5-imino-13-deoxydoxorubicin
  • 5(8H)-Naphthacenone, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-, (8R,10S)-
External IDs
  • GPX-150
  • GPX150

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
MargetuximabThe risk or severity of cardiotoxicity can be increased when Margetuximab is combined with GPX-150.
TrastuzumabThe risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with GPX-150.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Camsirubicin hydrochlorideQFO4NOX87K236095-24-2QVPRMGHPBJJSRU-IGAJXZAQSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Anthracenes / Hexoses / O-glycosyl compounds / Tetralins / Anisoles / Aryl ketones / P-quinonimines / Alkyl aryl ethers / Oxanes / Tertiary alcohols
show 13 more
Substituents
1,2-aminoalcohol / Acetal / Alcohol / Alkyl aryl ether / Alpha-hydroxy ketone / Amine / Aminoglycoside core / Anisole / Anthracene / Aromatic heteropolycyclic compound
show 29 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
7W3RB6E22W
CAS number
236095-29-7
InChI Key
UNNWAMSRSUVXCZ-PNISCQLKSA-N
InChI
InChI=1S/C27H30N2O10/c1-10-23(32)13(28)6-17(38-10)39-15-8-27(36,16(31)9-30)7-12-19(15)26(35)20-21(25(12)34)24(33)11-4-3-5-14(37-2)18(11)22(20)29/h3-5,10,13,15,17,23,29-30,32,34-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,23+,27-/m0/s1
IUPAC Name
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-12-imino-1-methoxy-5,7,8,9,10,12-hexahydrotetracen-5-one
SMILES
COC1=C2C(=N)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(=O)CO)C(O)=C3C(=O)C2=CC=C1

References

General References
Not Available
PubChem Compound
10392558
PubChem Substance
347829227
ChemSpider
32701310

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentSoft Tissue Sarcoma1
1CompletedTreatmentAdvanced Solid Tumors - Phase 1 Population1
1RecruitingTreatmentAdvanced Soft Tissue Sarcoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.331 mg/mLALOGPS
logP0.82ALOGPS
logP-0.099Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)8.1Chemaxon
pKa (Strongest Basic)9.36Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count12Chemaxon
Hydrogen Donor Count7Chemaxon
Polar Surface Area212.85 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity147.07 m3·mol-1Chemaxon
Polarizability54.93 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-056u-0104090000-f261f125ef8d4fb55c26
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0009130000-334108b1ffb9329742db
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000x-0009110000-098e2187e04504e940ef
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-002e-0508690000-a57bbc8d812fa8dbe7ea
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-03gl-1530920000-2387dad31a2ef10c254d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000y-1429640000-574f551a3d8a45d1436c
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-220.76202
predicted
DeepCCS 1.0 (2019)
[M+H]+222.5869
predicted
DeepCCS 1.0 (2019)
[M+Na]+228.5143
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2016 03:06 / Updated at September 28, 2023 05:47